EGFR and neoplasm: SIAHHigh/ON in TNBC residual tumors reflects that the EGFR/K-RAS/MAPK/SIAH pathway is ON, which indicates chemo-resistance, ineffective NACT/NST, and/or the need for additional adjuvant therapies to prevent progressive disease and early tumor relapse [Figure 2C].